Search Results

Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race.

• Authors : Taylor, Nick Paul (AUTHOR)

Subjects: NON-small-cell lung carcinoma; RAS oncogenes; ONCOGENES

• Source: FierceBiotech. 8/30/2024, pN.PAG-N.PAG. 1p.

Record details

Roche plots multi-KRAS attack, paying Hookipa $25M for arenaviral immunotherapy.

• Authors : Taylor, Nick Paul (AUTHOR)

Subjects: IMMUNOTHERAPY; RAS oncogenes; ONCOGENES

• Source: FierceBiotech. 10/20/2022, pN.PAG-N.PAG. 1p.

Record details

Verastem takes on debt to get RAS tumor program to finish line.

• Authors : Taylor, Nick Paul (AUTHOR)

Subjects: *DEBT; NON-small-cell lung carcinoma; RAS oncogenes

• Source: FierceBiotech. 3/28/2022, pN.PAG-N.PAG. 1p.

Record details

Mirati's 'very big' KRAS drug gets December decision date, further extending Lumakras' first-mover status.

• Authors : LaHucik, Kyle (AUTHOR)

Subjects: RAS oncogenes; NON-small-cell lung carcinomaAMGEN Inc. 039976196 AMGEN Inc. AMGEN Inc. 039976196 039976196 AMGEN Inc. 039976196 AMGN

• Source: FierceBiotech. 2/16/2022, pN.PAG-N.PAG. 1p.

Record details

A comprehensive overview of oncogenic pathways in human cancer.

• Authors : Li, Feng¹ (AUTHOR); Wu, Tan¹ (AUTHOR); Xu, Yanjun¹ (AUTHOR)

Subjects: CARCINOGENESIS; RAS oncogenes; CELL lines

• Source: Briefings in Bioinformatics. May2020, Vol. 21 Issue 3, p957-969. 13p.

Record details

Watch out, Amgen and Mirati. Boehringer's pan-KRAS inhibitor enters cancer clinical trials.

• Authors : Liu, Angus (AUTHOR)

Subjects: RAS oncogenes; CLINICAL trials; CANCERBOEHRINGER Ingelheim GmbH ; AMGEN Ltd.

• Source: FierceBiotech. 10/30/2019, pN.PAG-N.PAG. 1p.

Record details

Could a combo treatment boost KRAS inhibitors in lung cancer?

• Authors : Liu, Angus (AUTHOR)

Subjects: LUNG cancer; RAS oncogenes; RESEARCH teamsAMGEN Ltd.

• Source: FierceBiotech. 9/18/2019, pN.PAG-N.PAG. 1p.

Record details

Boehringer Ingelheim Targets KRAS Mutations with Lupin's LNP3794.

• Authors : Pahwa, Pratika; Liu, Michelle

Subjects: RAS oncogenesBOEHRINGER Ingelheim GmbH

• Source: PharmaDeals Review. Oct2019, Vol. 2019 Issue 10, p62-62. 1p.

Record details

Treating melanoma by turning off a common mutation.

• Authors : Liu, Angus

Subjects: MELANOMA treatment; RAS oncogenes; GENETIC mutation

• Source: FierceBiotech. 1/31/2019, pN.PAG-N.PAG. 1p.

Record details

SEBI issues detailed cybersecurity framework for KYC registration agencies.

Subjects: *EMPLOYEES; RAS oncogenes; INTERNET security

• Source: Ace Analyser: Company News. 10/16/2019, pN.PAG-N.PAG. 1p.

Record details